Healthcare: MannKind's Back from the Brink

Industry Focus - A podcast by The Motley Fool

Categories:

Business

A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker, Amarin. MNKD, UTHR, AMRN